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those obtained by DPS or GC-MS levels, suggesting that a fraction 
of Bu binds to blood cells.
Conclusion: This novel method can be applied with only 5 μ L of 
whole blood for routine therapeutic drug monitoring of Bu with 
accuracy and faster turnaround times in HSCT. Possibility of using 
capillary blood for dried blood sampling is under evaluation for its 
feasibility and accuracy to monitor Bu levels in pediatric patients.
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Introduction: Imatinib trough plasma concentrations (Cmin) have 
been correlated with treatment response in chronic myeloid leukemia 
(CML) patients. The use of Cmin monitoring for optimizing imatinib 
dosage (therapeutic drug monitoring [TDM]) is therefore proposed 
for patients with unsatisfying response or tolerance (“rescue TDM”). 
A cycle of “routine TDM” for dosage individualization could also 
be beneficial to prevent unfavorable events, yet its clinical usefulness 
has not been evaluated. We aimed to assess prospectively whether 
a “routine TDM” intervention targeting imatinib Cmin of 1000 ng/mL 
(tolerance, 750–1500 ng/mL) could improve efficacy, tolerance, and 
persistence on treatment compared with “rescue TDM” use only.
Patients (or Materials) and Methods: The Swiss Imatinib 
COncentration Monitoring Evaluation (I-COME) study was a multi-
center randomized controlled trial (ISRCTN31181395). Adult patients 
in chronic or accelerated phase CML receiving imatinib ≤5 years were 
eligible. Patients were randomly (1:1) allocated to receive “routine 
TDM” intervention or to serve as controls with access only to “res-
cue TDM”. All had 1-year follow-up. The primary endpoint was a 
combined efficacy-safety outcome (failure- and toxicity-free survival 
without imatinib discontinuation), analyzed in intention-to-treat.
Results: Among 56 CML recruited patients, 55 had their molecular 
and cytogenetic response measured. 14/27 of patients receiving “rou-
tine TDM” (52% [33%–71%]) remained event-free versus 16/28 of 
control patients with “rescue TDM” only (57% [39%–75%]; P = 
0.69). In the “routine TDM” group, dosage recommendations were 
adopted entirely in 50% of patients (median Cmin at study end, 895 
ng/mL; CV = 33%). These patients had fewer unfavorable events 
(28% [5%–52%]) compared with patients not receiving the advised 
dosage (77% [54%–99%]; P = 0.03; median Cmin at study end, 648 
ng/mL; CV = 38%).
Conclusion: This first prospective target concentration intervention 
trial could not formally demonstrate a benefit of “routine TDM” 
of imatinib, especially due to a small patient number and limited 
prescriber’s adherence to dosage recommendations. Nevertheless, 
the patients receiving the advised dosage more often met target 
concentrations and the combined outcome (efficacy, tolerance, and 
persistence). A cycle of routine TDM could thus be favorable, at 
least in patients eligible for dosage adjustment. Its usefulness should, 
however, be further confirmed in larger trials.
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Introduction: Ponesimod is a selective sphingosine-1 phosphate 
(S1P1) receptor modulator currently in clinical development for 
multiple sclerosis and plaque psoriasis. The aim of this study was 
to assess the maximum tolerated dose of increasing multiple doses 
(3-day titration steps) of ponesimod in healthy subjects.
Patients (or Materials) and Methods: This was a single-center, dou-
ble-blind, placebo-controlled, randomized, parallel-group, up-titra-
tion study in healthy male and female subjects (n = 16). The subjects 
received ascending oral doses either of ponesimod (n = 12) or placebo 
(n = 4) once daily for 3 days at each dose level (10 mg, 20 mg, 40 
mg, 60 mg, 80 mg, 100 mg). The pharmacodynamics of ponesimod 
were assessed by measuring the total lymphocyte count. The safety 
and tolerability was evaluated by monitoring adverse events, assess-
ing standard blood chemistry and hematology laboratory variables, 
12-lead ECG recordings and telemetry, measuring of vital signs, and 
pulmonary function tests (PFTs).
Results: A plateau in mean lymphocyte count reduction from base-
line of ~70% was reached at the 40-mg dose level. The most frequent 
adverse events, all of mild to moderate intensity, were chest discom-
fort (experienced by 58% of subjects), headache (50%), dizziness 
(42%), dyspnea (42%), abdominal pain (33%), and night sweats 
(25%). A transient decrease in heart rate was observed after adminis-
tration of the first 10-mg ponesimod dose (–9 bearts/min at 1.5 hours 
postdose [placebo, –2 beats/min]). After up-titration from 10 to 20 
mg (–7 beats/min at 1.5 hours postdose [placebo, –5 beats/min]) and 
following up-titration to higher doses, the decrease in heart rate with 
ponesimod was similar to placebo, suggesting that desensitization to 
the heart rate effect had occurred. A dose-dependent decrease in PFTs 
was observed and reached a plateau with 60-mg ponesimod (maximal 
mean decrease of 1.24 L [–30.5%] in forced expiratory volume in 1 
second [FEV1] and 0.70 L [–13.7%] in forced vital capacity [FVC]). 
At the dose levels of 80 to 100 mg, several subjects reported chest 
discomfort and dyspnea. The effects on heart rate, lymphocytes, and 
PFTs were fully reversible and reached baseline values within 10 days 
after discontinuation of treatment.
Conclusion: Ponesimod was tolerated by subjects exposed to doses 
of 10 to 100 mg during the 18-day up-titration regimen. The maxi-
Oral Communications Abstracts
2013 e7
mum tolerated dose was approached at 80 to 100 mg due to symp-
toms of chest discomfort and dyspnea. These results reveal a good 
safety margin to the highest dose selected for Phase 3 (20 mg).
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Introduction: Knowledge of adverse events (AEs) from biologic 
drugs used in pediatric population is limited. A recent Danish study 
analyzing AEs submitted to the Danish National Database indicated 
that off-label use of medicine in general to pediatric patients is associ-
ated with increased risk of AEs. The primary objective of the present 
study was to analyze the safety of off- and on-label use of biologic 
agents in a clinical sample of pediatric patients over a 3-year period 
and to identify potential risk factors associated with AEs.
Patients (or Materials) and Methods: A retrospective, longitudinal, 
study conducted in 1 pediatric department at Copenhagen University 
Hospital. Patients under the age of 18 years who received a minimum 
1 treatment with a biologic agent from January 1, 2009, through 
December 31, 2012, were included if they had been diagnosed with 
juvenile idiopathic arthritis (JIA) from 2009 to 2012. AEs and off-
label uses were identified by medical records review and classified 
according to the European Medical Agency guidelines. Multivariate 
logistic regression was used to investigate risk factors associated with 
an AE, and survival analysis was used to analyze time to an AE.
Results: 81 patients were included (65.4% females). Age ranged 
from 1 to 18 years (mean, 11.5 years). The 81 patients had a total 
of 133 courses of treatment with etanercept (49.6%), adalimumab 
(23.3%), infliximab (10.5%), golimumab (8.2%), tocilizumab 
(5.2%), and abatacept (3.0%). All patients were diagnosed with JIA 
(26 oligoarticular, 24 polyarticular, 2 systemic, 16 enthesitis-related 
JIA, and 16 JIA). Totally, 252 AEs were observed in 76% of the 
patients, 8 (3.2 %) of which were severe. 23.8% of the AEs had a 
treatment consequence (reduction in dose, treatment pause, discon-
tinuation of treatment) in 40.7% of the patients. After 200 days, 70% 
of all patients had experienced an AE. Gender, off-label use, type of 
drug, type of JIA, comedication, and comorbidity were not associ-
ated with an increased risk of AEs. Older age and severity of illness 
at time of treatment were the only significant predictors of AEs (P = 
0.0134, P < 0.0001). Off-label use was more likely with increasing 
number of treatment courses. Off-label use most often comprised of 
not recommended dose or indication. Time to an AE occurred did not 
differ with respect to type of drug or numbers of treatment courses.
Conclusion: AEs are frequent in this population of pediatric patients 
with juvenile idiopathic arthritis treated with biologic agents. Off-
label use was frequent but not associated with an increased risk of 
AEs.
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Introduction: Clinical trials (CT) and noninterventional trials 
(NIT) in Croatia are conducted in accordance with local laws (Drug 
law, and specific acts), and CT legislation is in accordance with 
European legislation. The Ministry of Health gives a final regula-
tory approval for CT. Since 2004, all clinical trials in Croatia have 
had to be reviewed by the Central Ethics Committee (CEC) and a 
favorable opinion must be issued before a clinical trial commences. 
Since December 2007, the CEC has also been responsible for issu-
ing opinions on noninterventional trials. During the trial evaluation 
procedure, CEC assesses scientific and ethical considerations of the 
trial. The aim of this analysis is to present the procedure of central 
evaluation and statistics of the CEC.
Patients (or Materials) and Methods: The database of the CEC is 
analyzed, and the trials are presented according to indication (topic), 
phase, and opinion issued after the first evaluation.
Results: According to a defined procedure and discussion, the CEC 
positive opinion has been given to 702 CT (since May 2004– 2012). 
During the last 5 years, 80 CT per year on average have had a posi-
tive opinion from the CEC. The greatest number of CT have been in 
the field of oncology (147), mental and behavioural disorders (95), 
and endocrine, nutritional, and metabolic diseases (88), and mostly 
Phase III trials. During the period of the last 5 years, CEC assessed 
67 NIT. The decisions after the first evaluation were conditionally 
positive or postponed opinion.
Conclusion: The model of centralized CT assessment through the 
Central Ethics Committee, as an independent body, has been con-
firmed during the investigated period as appropriate for Croatia. 
Furthermore, CEC assessment of NIT has also been confirmed as 
useful because this procedure, as a gatekeeper, prevents conducting 
the trials only for marketing purposes and allows in Croatia only 
NIT of certain quality and scientific merit.
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Introduction: Older people have often been excluded from preau-
thorization trials. Therefore, the regulatory ICH E7 guideline requires 
a minimal number of older subjects for trials regarding diseases pri-
marily related to aging (> 50% of database aged 65+) and for dis-
eases not typical for, but present in old age (> 100 subjects 65+). 
The study objective was to analyze the number of older people in 
trials of recently authorized drugs indicated for diseases that regularly 
present in old age.
Patients (or Materials) and Methods: Eligible drugs for this descrip-
tive study were registered by the European Medicines Agency 
between 2008 and 2011. Chosen indications: prevention of venous 
thromboembolism after replacement arthroplasty (dabigatran, rivar-
oxaban), osteoporosis (lasofoxifene, bazedoxifene, denosumab), 
atrial fibrillation (dronedarone, vernakalant), diabetes mellitus type 
